CA2613086A1 - Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles - Google Patents
Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles Download PDFInfo
- Publication number
- CA2613086A1 CA2613086A1 CA002613086A CA2613086A CA2613086A1 CA 2613086 A1 CA2613086 A1 CA 2613086A1 CA 002613086 A CA002613086 A CA 002613086A CA 2613086 A CA2613086 A CA 2613086A CA 2613086 A1 CA2613086 A1 CA 2613086A1
- Authority
- CA
- Canada
- Prior art keywords
- cerium oxide
- oxide nanoparticles
- nanoparticles
- treatment
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 282
- 229910000420 cerium oxide Inorganic materials 0.000 title claims abstract description 236
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 title claims abstract description 236
- 230000003110 anti-inflammatory effect Effects 0.000 title description 6
- 230000004223 radioprotective effect Effects 0.000 title description 6
- 230000002708 enhancing effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 189
- 238000011282 treatment Methods 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 238000000338 in vitro Methods 0.000 claims abstract description 25
- 238000001727 in vivo Methods 0.000 claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 230000009286 beneficial effect Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 114
- 150000003254 radicals Chemical class 0.000 claims description 80
- 239000002245 particle Substances 0.000 claims description 57
- 230000006378 damage Effects 0.000 claims description 53
- 208000014674 injury Diseases 0.000 claims description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 230000000694 effects Effects 0.000 claims description 41
- 208000027418 Wounds and injury Diseases 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 25
- 238000004113 cell culture Methods 0.000 claims description 23
- 208000035475 disorder Diseases 0.000 claims description 23
- 230000002265 prevention Effects 0.000 claims description 23
- 230000008733 trauma Effects 0.000 claims description 19
- 206010061218 Inflammation Diseases 0.000 claims description 17
- 230000004054 inflammatory process Effects 0.000 claims description 17
- 230000005855 radiation Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 238000003980 solgel method Methods 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000005054 agglomeration Methods 0.000 claims description 5
- 230000002776 aggregation Effects 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 4
- 210000002977 intracellular fluid Anatomy 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 239000002953 phosphate buffered saline Substances 0.000 claims description 4
- 230000001950 radioprotection Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000014644 Brain disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000034423 Delivery Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000029033 Spinal Cord disease Diseases 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000007613 environmental effect Effects 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 210000001525 retina Anatomy 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 238000011269 treatment regimen Methods 0.000 claims description 3
- 230000009677 vaginal delivery Effects 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 238000012007 large scale cell culture Methods 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 5
- 230000004071 biological effect Effects 0.000 abstract description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 46
- 210000000274 microglia Anatomy 0.000 description 37
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 22
- 210000001130 astrocyte Anatomy 0.000 description 21
- 210000004958 brain cell Anatomy 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 241000255925 Diptera Species 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 239000002158 endotoxin Substances 0.000 description 17
- -1 oxygen radicals Chemical class 0.000 description 17
- 235000013305 food Nutrition 0.000 description 16
- 229920006008 lipopolysaccharide Polymers 0.000 description 16
- 210000002569 neuron Anatomy 0.000 description 15
- 230000030833 cell death Effects 0.000 description 14
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 14
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 14
- 230000004224 protection Effects 0.000 description 14
- 229910052684 Cerium Inorganic materials 0.000 description 13
- 230000005779 cell damage Effects 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 229940123457 Free radical scavenger Drugs 0.000 description 11
- 229930003427 Vitamin E Natural products 0.000 description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 11
- 230000000069 prophylactic effect Effects 0.000 description 11
- 239000002516 radical scavenger Substances 0.000 description 11
- 230000000451 tissue damage Effects 0.000 description 11
- 235000019165 vitamin E Nutrition 0.000 description 11
- 229940046009 vitamin E Drugs 0.000 description 11
- 239000011709 vitamin E Substances 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 230000001143 conditioned effect Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 9
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 9
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 9
- 229960003987 melatonin Drugs 0.000 description 9
- 230000016273 neuron death Effects 0.000 description 9
- 230000008816 organ damage Effects 0.000 description 9
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 8
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 8
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 8
- 229960004308 acetylcysteine Drugs 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000007760 free radical scavenging Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000000695 excitation spectrum Methods 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 230000000284 resting effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 208000037887 cell injury Diseases 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000004660 morphological change Effects 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000003104 tissue culture media Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000255601 Drosophila melanogaster Species 0.000 description 4
- 206010019196 Head injury Diseases 0.000 description 4
- 102000003839 Human Proteins Human genes 0.000 description 4
- 108090000144 Human Proteins Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000019155 Radiation injury Diseases 0.000 description 4
- 241000255588 Tephritidae Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 206010073306 Exposure to radiation Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000765 microspectrophotometry Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000006764 neuronal dysfunction Effects 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 238000012342 propidium iodide staining Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101000585552 Bacillus anthracis Protective antigen Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229960002520 hepatitis vaccine Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003585 interneuronal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000005089 vacuolized cytoplasm Anatomy 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69393005P | 2005-06-27 | 2005-06-27 | |
| US60/693,930 | 2005-06-27 | ||
| PCT/US2006/024963 WO2007002662A2 (en) | 2005-06-27 | 2006-06-27 | Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2613086A1 true CA2613086A1 (en) | 2007-01-04 |
Family
ID=37595977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002613086A Abandoned CA2613086A1 (en) | 2005-06-27 | 2006-06-27 | Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100166821A1 (enExample) |
| EP (1) | EP1904072A4 (enExample) |
| JP (1) | JP2008546842A (enExample) |
| AU (1) | AU2006261764A1 (enExample) |
| CA (1) | CA2613086A1 (enExample) |
| WO (1) | WO2007002662A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116270729A (zh) * | 2022-11-09 | 2023-06-23 | 西安交通大学医学院第一附属医院 | 多孔纳米棒状氧化铈在制备治疗特应性皮炎的药物中的应用 |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10857178B2 (en) * | 2005-06-27 | 2020-12-08 | Edward Via Virginia College Of Osteopathic Medicine | Cerium oxide nanoparticles for treatment and prevention of Alzheimer's disease, Parkinson's disease, and disorders associated with free radical production and/or mitochondrial dysfunction |
| US9649337B2 (en) | 2005-06-27 | 2017-05-16 | Edward Via Virginia College Of Osteopathic Medicine | Cerium oxide nanoparticles for the treatment and prevention of stroke and cardiovascular disease |
| US7959949B2 (en) | 2006-04-27 | 2011-06-14 | University Of Central Florida Research Foundation, Inc. | Functionalized nanoceria composition for ophthalmic treatment |
| WO2008018932A2 (en) | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
| US8333993B1 (en) * | 2006-12-29 | 2012-12-18 | University Of Central Florida Research Foundation, Inc. | Synthesis of polymer coated ceria nanoparticles for biomedical applications |
| US20080166412A1 (en) | 2007-01-02 | 2008-07-10 | Kiminobu Sugaya | Methods and materials for stimulating proliferation of stem cell |
| KR100876361B1 (ko) * | 2007-05-11 | 2008-12-29 | 주식회사 태웅이엘에스 | 슬리밍용 조성물 |
| US9119391B1 (en) * | 2007-07-16 | 2015-09-01 | University Of Central Florida Research Foundation, Inc. | Polymer coated ceria nanoparticles for selective cytoprotection |
| EP2288258A4 (en) * | 2008-04-25 | 2012-10-31 | Univ Oklahoma | INHIBITION OF NEOVASCULARIZATION BY CERIUM OXIDE NANOPARTICLES |
| US8916199B1 (en) | 2008-04-25 | 2014-12-23 | University of Central Florida Research Foundation, Ind. | Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide |
| US9127202B1 (en) | 2008-07-18 | 2015-09-08 | University Of Central Florida Research Foundation, Inc. | Biocompatible nano rare earth oxide upconverters for imaging and therapeutics |
| US8883519B1 (en) | 2009-03-17 | 2014-11-11 | University Of Central Florida Research Foundation, Inc. | Oxidase activity of polymeric coated cerium oxide nanoparticles |
| US9585840B1 (en) | 2009-07-10 | 2017-03-07 | University Of Central Florida Research Foundation, Inc. | Redox active cerium oxide nanoparticles and associated methods |
| US8795731B1 (en) | 2009-10-12 | 2014-08-05 | University Of Central Florida Research Foundation, Inc. | Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation |
| US20160074434A1 (en) * | 2010-07-22 | 2016-03-17 | University Of Central Florida Research Foundation, Inc. | Application Device for Inducing Cytotoxicity to Tumor Cells Via Coated Cerium Oxide Nanoparticles |
| WO2012036786A1 (en) | 2010-09-17 | 2012-03-22 | University Of L'aquila | Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease |
| DK201000969A (en) * | 2010-10-25 | 2012-04-26 | Entomopharm Aps | Insect-based ex vivo model for testing blood-brainbarrier penetration and method for exposinginsect brain to nanoparticles |
| US11116792B1 (en) | 2010-12-22 | 2021-09-14 | Biocurity Holdings, Inc. | Cerium oxide nanoparticle formulation for use in skin radioprotection and associated methods |
| US8951539B1 (en) | 2011-06-07 | 2015-02-10 | University Of Central Florida Research Foundation, Inc. | Methods of promoting angiogenesis using cerium oxide nanoparticles |
| US9161950B2 (en) | 2011-09-21 | 2015-10-20 | University Of Central Florida Foundation, Inc. | Neuronal protection by cerium oxide nanoparticles |
| CA2869554A1 (en) * | 2012-04-04 | 2013-10-10 | Duke University | Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury |
| WO2013158744A2 (en) | 2012-04-17 | 2013-10-24 | Cerion Enterprises, Llc | Nanoparticles of cerium and amino acids |
| US9446070B2 (en) | 2012-06-13 | 2016-09-20 | Cerion, Llc | Nanoceria with citric acid additive |
| JP6174692B2 (ja) | 2012-06-13 | 2017-08-02 | セリオン エンタープライジズ リミテッド ライアビリティ カンパニー | 酸化ストレスの処置のためのナノセリア |
| WO2014008503A1 (en) * | 2012-07-06 | 2014-01-09 | University Of Central Florida Research Foundation, Inc. | Methods of using ceo2 and tio2 nanoparticles in modulation of the immune system |
| US9463437B2 (en) | 2013-02-14 | 2016-10-11 | University Of Central Florida Research Foundation, Inc. | Methods for scavenging nitric oxide using cerium oxide nanoparticles |
| WO2014134286A2 (en) * | 2013-03-01 | 2014-09-04 | University Of Central Florida Research Foundation, Inc. | Cerium oxide nanoparticles accelerate the decay of peroxynitrite (onoo-) |
| US9549950B2 (en) | 2013-04-25 | 2017-01-24 | Cerion, Llc | Chelated nanoceria for the treatment of oxidative stress |
| US9623110B2 (en) | 2013-08-09 | 2017-04-18 | Cerion, Llc | Nanoparticles of a metal and a nucleobase |
| WO2015058037A1 (en) | 2013-10-17 | 2015-04-23 | Cerion, Llc | Malic acid stabilized nanoceria particles |
| US9669055B1 (en) * | 2014-04-11 | 2017-06-06 | Marshall University Research Corporation | Methods for treating sepsis |
| CN103983777A (zh) * | 2014-05-07 | 2014-08-13 | 大连理工大学 | 一种基于纳米二氧化铈仿生氧化酶的微囊藻毒素比色检测方法 |
| AU2015289504B2 (en) * | 2014-07-17 | 2020-12-17 | BioCurity Pharmaceuticals Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| JP2018508568A (ja) | 2015-01-20 | 2018-03-29 | セリオン，リミティド ライアビリティ カンパニー | カタラーゼ様活性を有するｅｄｄｓでキレート化されたナノセリア |
| JP2016204368A (ja) * | 2015-04-14 | 2016-12-08 | 株式会社Ａｐｐｌａｕｓｅ | 酸化セリウム微粒子を含有する組成物 |
| US11389536B2 (en) | 2015-07-17 | 2022-07-19 | BioCurity Pharmaceuticals Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| US11833172B2 (en) | 2015-11-25 | 2023-12-05 | The Regents Of The University Of Colorado | Use of microRNA-146A and nanoceria conjugate to improve wound healing and promote tissue regeneration |
| KR101696903B1 (ko) | 2016-04-20 | 2017-01-17 | 서울대학교병원 | 세리아 나노복합체를 포함하는 비외상성 두개내 출혈 치료용 약학적 조성물 |
| CN107789627B (zh) * | 2017-09-26 | 2021-05-07 | 西北农林科技大学 | 可降解聚多巴胺包封的靶向双刺激响应性多功能二氧化铈纳米载药体系 |
| KR102102535B1 (ko) * | 2018-07-26 | 2020-04-21 | 서울대학교산학협력단 | 방사선 보호 나노입자 |
| EP3867407A4 (en) * | 2018-07-26 | 2022-09-14 | Edward Via College of Osteopathic Medicine | BLOOD PRESERVATION COMPOSITIONS, DEVICES, AND USES THEREOF |
| JP7328480B2 (ja) * | 2018-09-14 | 2023-08-17 | 株式会社applause Pharma | チロシン－チロシナーゼ反応阻害剤 |
| WO2020069292A1 (en) * | 2018-09-28 | 2020-04-02 | The Regents Of The University Of Colorado, A Body Corporate | Methods for preventing and treating pulmonary inflammation and fibrosis |
| CN112516294B (zh) * | 2020-12-22 | 2023-04-07 | 浙江大学 | 一种氧化铈纳米稳定剂在制备预防过敏性疾病药物中的应用及预防过敏性疾病的药物组合物 |
| US12480009B2 (en) | 2021-07-30 | 2025-11-25 | Xheme Inc. | Nanoporous cerium oxide nanoparticle macro-structure |
| WO2023060246A1 (en) * | 2021-10-08 | 2023-04-13 | Xheme Inc. | Blood preservation compositions, devices and uses thereof utilizing: a. zirconium dioxide nanoparticles or nanoporous zirconium dioxide nanoparticle macrostructures; and b. nanoporous cerium oxide nanoparticle macrostructures |
| CN116942695A (zh) * | 2022-04-20 | 2023-10-27 | 中国科学院深圳先进技术研究院 | 二氧化铈作为炎症小体抑制剂在疾病治疗中的应用 |
| AU2024285952A1 (en) * | 2023-06-09 | 2025-12-04 | Xheme Inc. | Bioreactors providing cerium oxide and zirconium dioxide |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG38903A1 (en) * | 1995-03-16 | 1997-04-17 | Gen Electric | Acrylic coatings containing inorganic UV screen |
| JP2746861B2 (ja) * | 1995-11-20 | 1998-05-06 | 三井金属鉱業株式会社 | 酸化セリウム超微粒子の製造方法 |
| US6413489B1 (en) * | 1997-04-15 | 2002-07-02 | Massachusetts Institute Of Technology | Synthesis of nanometer-sized particles by reverse micelle mediated techniques |
| GB0126663D0 (en) * | 2001-11-06 | 2002-01-02 | Oxonica Ltd | Cerium oxide nanoparticles |
| US6669823B1 (en) * | 2002-06-17 | 2003-12-30 | Nanophase Technologies Corporation | Process for preparing nanostructured materials of controlled surface chemistry |
| US7534453B1 (en) * | 2002-09-05 | 2009-05-19 | University Of Central Florida Research Foundation, Inc. | Cerium oxide nanoparticles and use in enhancing cell survivability |
| JP4054869B2 (ja) * | 2002-12-25 | 2008-03-05 | 独立行政法人産業技術総合研究所 | 抵抗型酸素センサの酸素分圧検出部分の製造方法 |
| DE10337199A1 (de) * | 2003-08-13 | 2005-03-10 | Degussa | Ceroxidpulver |
| CA2610296C (en) * | 2005-04-29 | 2016-06-14 | University Of Central Florida Research Foundation, Inc. | Inhibition of reactive oxygen species and protection of mammalian cells |
-
2006
- 2006-06-27 EP EP06785640A patent/EP1904072A4/en not_active Ceased
- 2006-06-27 CA CA002613086A patent/CA2613086A1/en not_active Abandoned
- 2006-06-27 WO PCT/US2006/024963 patent/WO2007002662A2/en not_active Ceased
- 2006-06-27 JP JP2008519483A patent/JP2008546842A/ja active Pending
- 2006-06-27 AU AU2006261764A patent/AU2006261764A1/en not_active Abandoned
- 2006-06-27 US US11/993,260 patent/US20100166821A1/en not_active Abandoned
-
2012
- 2012-07-02 US US13/539,564 patent/US8747907B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116270729A (zh) * | 2022-11-09 | 2023-06-23 | 西安交通大学医学院第一附属医院 | 多孔纳米棒状氧化铈在制备治疗特应性皮炎的药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20130004584A1 (en) | 2013-01-03 |
| AU2006261764A1 (en) | 2007-01-04 |
| WO2007002662A3 (en) | 2007-11-22 |
| JP2008546842A (ja) | 2008-12-25 |
| EP1904072A4 (en) | 2009-06-17 |
| US20100166821A1 (en) | 2010-07-01 |
| WO2007002662A2 (en) | 2007-01-04 |
| US8747907B2 (en) | 2014-06-10 |
| EP1904072A2 (en) | 2008-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8747907B2 (en) | Anti-inflammatory, radioprotective, and longevity enhancing capabilities of ceriumoxide nanoparticles | |
| CN104220057B (zh) | 药物组合物和方法 | |
| KR102184722B1 (ko) | 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도 | |
| JP6295249B2 (ja) | レチノイドアゴニストを用いた好中球減少症の治療方法 | |
| Le et al. | Implant healing in experimental animal models of diabetes | |
| KR20200128659A (ko) | 방사선방호를 위해 RRx-001을 이용하는 방법 및 조성물 | |
| Martins et al. | Biocompatibility analysis of chemomechanical caries removal material Papacarie on cultured fibroblasts and subcutaneous tissue | |
| TWI327919B (en) | Precursor of n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme | |
| US9649337B2 (en) | Cerium oxide nanoparticles for the treatment and prevention of stroke and cardiovascular disease | |
| JPH10502371A (ja) | リンホトキシンを用いる癌処置法 | |
| JPH10511974A (ja) | リソチーム二量体の新しい応用 | |
| Verma et al. | Metal nanoparticle based antibacterial nanocomposites for skin infections | |
| Rani et al. | Metallic Nanoparticles Applications in Medicine | |
| WO2010083636A1 (zh) | 小牛血去蛋白提取物的滴眼液 | |
| EP4149420B1 (en) | Protease formulation for treatment of microbial infections | |
| US20190234933A1 (en) | Compositions and assays | |
| US20240156875A1 (en) | Equine-specific therapeutic compositions and methods of use | |
| TWI886392B (zh) | 一種番紅花酸製備方法及抗氧化之保護眼睛用途 | |
| CN118021939A (zh) | Bmp4蛋白或其衍生物在制备药物中的用途 | |
| US20240415937A1 (en) | Theophylline-loaded collagen nanoparticles | |
| Zhang et al. | Black Phosphorus Quantum Dots Effectively and Safely Treat Glaucoma as a Promising Anti-Ferroptosis Nano-drug | |
| CN118021805A (zh) | 一种新型的辐射损伤保护剂及其应用 | |
| DE19643093C2 (de) | Verwendung von FasL oder mit FasL transfizierten CD4·+·/FasL·-·/TH1-Zellinien oder von FasL in Kombination mit einem oder mehreren Cytokin(en) zur Bekämpfung von TH1/TH2-Krankheiten | |
| CN120324578A (zh) | 一种trem-1抑制肽纳米颗粒及其制备方法和应用 | |
| WO2009042708A1 (en) | Regeneration anti-inflammatory composition and method for treating a retinal dystrophy using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |